Bausch & Lomb says warning letter issues mainly addressed
This article was originally published in Clinica
Bausch & Lomb says the issues outlined in a warning letter from the FDA dated October 31 have already been largely addressed. The letter refers to the agency's March-May 2006 inspection of the company's Greenville, South Carolina manufacturing site, which culminated in the eye care company recalling its ReNu with MoistureLoc lens care solution following an outbreak of Fusarium keratitis (Clinica passim).
You may also be interested in...
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.
Third round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.